

IN THE CLAIMS:

Please cancel claims 3 and 24-25 without prejudice or disclaimer.

Please amend claims 1-2, 10-11, 16, 21 and 23-24 in the following manner:

A¹ Sub B2
1. (Amended) A liposomal topotecan unit dosage form, said unit
dosage form comprising:
a lipid; and
a topotecan dosage of from about 0.01 mg/M²/dose to about 7.5
mg/M²/dose, wherein said liposomal topotecan unit dosage form has a drug:lipid ratio by
weight of about 0.05 to about 0.2 and wherein said lipid comprises a mixture of
sphingomyelin and cholesterol.

2. (Amended) The liposomal topotecan unit dosage form of claim 1,
wherein said drug:lipid ratio by weight is about 0.05 to about 0.15.

A² Sub B2
10. (Amended) The liposomal topotecan formulation of claim 8,
comprising a drug:lipid ratio by weight of about 0.05 to about 0.2.

11. (Amended) The liposomal topotecan formulation of claim 10,
wherein said drug:lipid ratio by weight is about 0.05 to about 0.15.

A³
16. (Amended) A method of treating solid tumors in a mammal, said
method comprising:
administering to said mammal having a solid tumor of the lung, mammary
and/or colon a liposomal topotecan formulation having a drug:lipid ratio by weight of
about 0.05 to about 0.2.